KELUN-BIOTECH ANNOUNCES 2025 INTERIM RESULTS

About this update from Sichuan Kelun-biotech Biopharmaceutical Co., Ltd. Class H

[{"type":"list","items":[{"val":[{"type":"text","content":"Revenue reached approximately RMB950.4 million, with total commercial sales RMB309.8million, representing a significant increase in proportion","length":142,"tagName":"p"}]},{"val":[{"type":"text","content":"Research and development expenses was approximately RMB611.5 million","length":68,"tagName":"p"}]},{"val":[{"type":"text","content":"Loss for the period was RMB145.2 million; adjusted loss for the period[1] was RMB69.4 million","length":93,"tagName":"p"}]},{"val":[{"type":"text","content":"Cash and cash equivalents[2] amounted to approximately RMB4527.8 million, reflecting ample cash reserves","length":104,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":407,"olType":false},{"type":"table","headerItems":[],"items":[{"val":[{"colspan":"1","rowspan":"1","style":"PADDING-RIGHT:0.17em;PADDING-LEFT:0.17em;VERTICAL-ALIGN:BOTTOM;","val":[{"type":"text","content":"Note1: Calculated by deducting equity-settled share-based payment from loss for the year.","length":94,"tagName":"p","attribs":{}}]}]},{"val":[{"colspan":"1","rowspan":"1","style":"PADDING-RIGHT:0.17em;PADDING-LEFT:0.17em;VERTICAL-ALIGN:BOTTOM;","val":[{"type":"text","content":"Note2: Comprises cash and cash equivalents, restricted deposits, financial assets measured at fair value through profit or loss, financial assets measured at amortized cost and financial assets measured at fair value through other comprehensive income.","length":257,"tagName":"p","attribs":{}}]}]}],"length":352},{"type":"text","content":" ","length":6,"tagName":"p"},{"type":"text","content":"CHENGDU, China, Aug. 18, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Pharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", Stock Code: 6990.HK) announced its unaudited interim results for the six months ended 30 June 2025 (the "Reporting Period").","length":292,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/四川科倫博泰生物醫藥股份有限公司)","displaySize":"","headline":null,"caption":"(PRNewsfoto/四川科倫博泰生物醫藥股份有限公司)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":116,"url":"https://media.zenfs.com/en/prnewswire.com/5455aad5e4ea0b08ff580f6c7e42974...

More updates from Sichuan Kelun-biotech Biopharmaceutical Co., Ltd. Class H